Drug Profile
Diabetes type 1 vaccine oral - Diamyd Therapeutics
Alternative Names: OramydLatest Information Update: 21 Feb 2013
Price :
$50
*
At a glance
- Originator Diamyd Therapeutics; GTC Biotherapeutics
- Developer Diamyd Therapeutics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
- 15 Oct 2002 Suspended - Preclinical for Type-1 diabetes mellitus in Sweden (PO)
- 19 Jun 2002 Genzyme Transgenics Corporation is now called GTC Biotherapeutics